Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital declines year over year

Q1 FY2026 other working capital of $1.51M (cash outflow) fell 91.1% year over year, behind the -71.6% change in trailing-twelve-month other working capital. Over 3 fiscal years it compounded at +51.1% a year.

Context

  • Other working capital amounted to 51.5% of revenue in FY2025, up 14.8 pp from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -91.1% toward the trailing-twelve-month pace of -71.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.51M-177.8% QoQ
Last fiscal yearDec 2025
-$34.65M-31.8% YoY
LTMMar 2026
-$19.64M-71.6% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-91.1%——
1 year-31.8%——
3-year CAGR+51.1%——
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
(34.65M) USD
Year-over-year change
+31.8%

Other Working Capital vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -71.6% is the 8th highest of 10, against a peer median of +76.5%.
  • Other working capital amounts to 43.3% of revenue for ARCT, versus a peer median of 47.1%.
ARCT Competitors
Other Working Capital for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$73.38M USD-319.4%-36.2%112.0%
NVAXNovavax, Inc.LTM Mar 2026$69.9M USD-86.8%-15.9%11.7%
VALNValneva SELTM Mar 2026€25.29M EUR+214.1%-60.1%16.2%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$19.64M USD-71.6%+51.1%43.3%
ABUSArbutus Biopharma CorporationLTM Mar 2026$16.41M USD+7981.6%—8.6%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$11.83M USD+225.4%——
PRQRProQR Therapeutics N.V.LTM Mar 2026€10.48M EUR-2.6%+49.7%78.0%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$9.99M USD+435.9%+32.1%—
SLNSilence Therapeutics plcLTM Mar 2026$8.34M USD——905.3%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.17M USD-37.3%-32.4%—
BNTCBenitec Biopharma Inc.LTM Mar 2026$998.82K USD+76.5%——
Peer median (excluding ARCT) —+76.5%-24.2%47.1%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
Deferred Income Tax00000
Stock-Based Compensation28.92M30.61M34.65M37.99M25.41M
Change in Working Capital32.63M(12.56M)7.38M(20.81M)(39.2M)
Accounts Receivables(1.24M)603K(29.3M)28.09M(1.59M)
Inventory00000
Accounts Payables(769K)(3.11M)(2.24M)1.92M(2.96M)
Other Working Capital34.64M(10.05M)38.92M(50.81M)(34.65M)
Other Non-Cash Items5.9M3.06M(33.36M)471K2.28M
Operating Cash Flow(135.04M)31.99M(18.1M)(59.75M)(74.27M)
Capital Expenditures(3.41M)(7.73M)(2.9M)(648K)(230K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(3.41M)(7.73M)(2.9M)(648K)(230K)
Debt Repayment46.6M(5M)(27.36M)00
Common Stock Issued515K411K609K682K13.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities902K1.73M2.67M4.74M0
Financing Cash Flow48.02M(2.86M)(24.09M)5.42M13.38M
Effect of Forex Changes00000
Net Change in Cash(90.43M)21.41M(45.09M)(54.98M)(61.12M)
Free Cash Flow(138.45M)24.27M(21M)(60.4M)(74.27M)

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.